The short answer
Semaglutide itself is not illegal in Ireland. It is a licensed active substance with more than one authorised medicinal product built around it, and those products can be legally prescribed and dispensed today. What changes the legal picture is the specific formulation, the specific brand, and whether the source of supply sits inside or outside the regulated chain. Confusing "semaglutide is legal" with "any product calling itself semaglutide is legal" is the single most common misunderstanding people run into, and it is the one this article is written to clear up.
Available in Ireland since March 2025 through the EMA centralised procedure. Classified as a prescription-only medicine (POM). No HSE reimbursement scheme covers it as of 2026 — patients currently pay privately for the medicine and the associated prescriber visits.
A higher-dose oral tablet aimed specifically at weight management has not received a marketing authorisation anywhere in the EU, including Ireland, as of 2026. This is separate from the lower-dose oral tablet already authorised for type 2 diabetes.
Ozempic, Wegovy, Rybelsus — three brands, one molecule, different rules
Semaglutide reaches the Irish market under more than one brand name, and each brand carries its own marketing authorisation, its own approved indication, and its own dose. Ozempic is the injectable formulation authorised for type 2 diabetes and has been available in Ireland for several years. Wegovy is a higher-dose injectable formulation of the same molecule, authorised specifically for chronic weight management, and it reached the Irish market in March 2025. Rybelsus is an oral tablet, but it is authorised only at the lower dose used for type 2 diabetes — not at a dose intended for weight management.
This distinction matters because a marketing authorisation is granted for a specific product, at a specific strength, for a specific indication — not for a molecule in the abstract. A product being legal for diabetes does not make an unregistered, higher-dose version of it legal for weight loss, and a tablet being authorised for one indication does not extend automatically to a different formulation aimed at a different use.
Why Wegovy has no HSE reimbursement, and what that does and does not mean
As of 2026, Wegovy has not been added to the HSE's High Tech Drugs Scheme or the Long Term Illness scheme, the two main routes through which the state funds ongoing medication costs. That means a patient with a valid prescription is currently paying for Wegovy out of pocket rather than through a state subsidy.
This is a reimbursement question, not a legality question. Wegovy remains a fully authorised, prescription-only medicine in Ireland regardless of who pays for it. Reimbursement decisions go through a separate health-technology-assessment process at the National Centre for Pharmacoeconomics and can change independently of the medicine's authorisation status. A lack of state funding today does not indicate that the product is unlicensed, experimental, or restricted for safety reasons.
Mapping the HPRA's classification tiers
The Health Products Regulatory Authority (HPRA) is Ireland's competent authority for medicines, operating within the EU regulatory framework alongside the European Medicines Agency (EMA). Every semaglutide product circulating in Ireland falls into one of four distinct tiers, and understanding which tier a given product occupies is the entire legal question.
- Tier 1 — Authorised prescription-only medicine (POM)Ozempic, Wegovy, and Rybelsus at their approved doses and indications. Each holds an EMA centralised marketing authorisation recognised by the HPRA. Legal to prescribe and dispense in Ireland through a registered pharmacy, against a valid prescription.
- Tier 2 — Authorised medicine, off-label prescribingA registered prescriber may in some circumstances prescribe an authorised product outside its licensed indication, using clinical judgement. The product itself remains a genuine, HPRA-recognised medicine — the prescribing decision is what sits outside the label, not the product's legal status.
- Tier 3 — Unlicensed or unauthorised productsRaw semaglutide powder, unregistered peptide vials, or injectable products sold as "research" or "cosmetic" material with no HPRA or EMA marketing authorisation. These fall outside the Irish Medicines Regulations and the EU pharmaceutical framework, and supplying them for human use is not lawful regardless of how they are marketed or labelled.
- Tier 4 — Falsified or counterfeit medicinesProducts packaged to imitate an authorised brand such as Wegovy or Ozempic but not manufactured by the authorisation holder. These are addressed under the EU Falsified Medicines Directive and Irish enforcement law, and they represent the most serious category, since the packaging is designed to deceive rather than simply omit a licence.
What HPRA enforcement has found in unlicensed products
The surge in demand for GLP-1-class medicines since 2023 has been matched by a parallel surge in unlicensed and falsified products entering Ireland through online sellers and informal supply chains. HPRA enforcement operations, working alongside customs authorities, have intercepted and seized tens of thousands of units of illegal semaglutide-branded injectable products over the past two years — vials and pens presented as weight-loss medicines but lacking any valid marketing authorisation or traceable manufacturing record.
Testing of intercepted material from this category, both in Ireland and in comparable enforcement actions across the EU and UK, has repeatedly turned up product that does not match its labelling: some samples contain no detectable active ingredient at all, while others carry contamination or an incorrect concentration of active substance. None of this testing happens within the authorised supply chain, because these products were never part of it. A vial that never passed through an EMA-authorised manufacturing and batch-release process carries no verified guarantee about what it actually contains.
A Certificate of Analysis attached to an unlicensed semaglutide product cannot substitute for the HPRA's own regulatory oversight of an authorised medicine. Authorised batches of Ozempic and Wegovy pass through a manufacturing and quality-release process governed by the marketing authorisation itself, checked against a specification lodged with the EMA. An unlicensed seller's certificate has no such regulatory standing, no matter how professional it looks or what testing methods it references.
Where this leaves someone trying to understand their legal position
If the product in question is Ozempic, Wegovy, or Rybelsus, dispensed by an Irish pharmacy against a prescription from a registered prescriber, the legal position is straightforward: it is an authorised medicine, and the only open question is who pays for it. If the product is a powder, an unbranded vial, or anything sold outside a pharmacy without a prescription, it sits in the unlicensed or falsified tiers described above, and Irish and EU medicines law does not recognise it as a legitimate medicinal product regardless of any documentation supplied with it.
Disclaimer: This article is an educational overview of publicly available regulatory information. It does not constitute legal advice, medical advice, or a recommendation to obtain or use any product. Consult the HPRA's and EMA's official publications and a qualified healthcare professional for current, case-specific guidance. Get the COA does not sell products and does not give medical advice.
Sources: Wilding et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," NEJM 2021 (PMID 33567185) · European Medicines Agency (EMA) — Wegovy EPAR (ema.europa.eu) · Health Products Regulatory Authority (HPRA) (hpra.ie). Information only. Updated 26 July 2026.